ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development

ImpriMed 将离体功能测试与多模态人工智能相结合，以支持个性化癌症治疗决策和药物研发

The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia

该笔投资是ImpriMed公司1000万美元A2轮过桥融资的一部分，旨在推动公司在美国的商业化进程并拓展亚洲市场。

NAVER D2SF to strengthen its global healthcare founder community through its healthcare network and go-to-market expertise

NAVER D2SF 将依托其医疗行业网络及市场进入专业优势，强化其全球医疗健康领域创业者社区

SEOUL, South Korea

韩国首尔

,

，

Sept. 18, 2026

2026年9月18日

/PRNewswire/ -- NAVER D2SF, NAVER's inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed's $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalized treatment decisions.

/美通社/ -- NAVER D2SF（NAVER旗下的企业内部风险投资部门）已对总部位于硅谷的精准医疗公司ImpriMed进行投资，参与了ImpriMed的1000万美元A2轮过桥融资。ImpriMed开发由人工智能驱动的精准医疗解决方案，将源自患者的活体癌细胞离体分析与基因组、免疫表型及临床数据相结合，以支持个性化治疗决策。

NAVER D2SF's investment reflects ImpriMed's commercial and clinical experience in the U.S. healthcare market and its growing capabilities across precision medicine and drug development..

NAVER D2SF 的投资反映了 ImpriMed 在美国医疗市场的商业和临床经验，以及其在精准医学和药物开发领域不断增强的能力。

Precision oncology increasingly relies on integrating multiple types of patient data to account for differences in disease biology and treatment response. ImpriMed applies multimodal AI to patient-specific cancer cell characteristics, drug response profiles, and clinical information to enable more personalized treatment selection..

精准肿瘤学日益依赖于整合多种类型的患者数据，以解释疾病生物学和治疗反应方面的差异。ImpriMed 将多模态人工智能应用于患者特定的癌细胞特征、药物反应谱和临床信息，从而实现更加个性化的治疗方案选择。

At the core of ImpriMed's xCellSense

ImpriMed xCellSense 的核心

®

®

platform is its ability to keep patient cancer cells viable ex vivo for extended periods, enabling evaluation of their biological characteristics and drug sensitivity. The platform combines these results with immunophenotypic, genomic, and clinical data to guide treatment decisions. ImpriMed is developing AI models trained on more than 3.5 million data points, combining real-world data with functional cell analysis to improve predictive accuracy..

该平台的优势在于能够在体外长期保持患者癌细胞的活性，从而评估其生物学特性和药物敏感性。平台将这些结果与免疫表型、基因组学和临床数据相结合，以指导治疗决策。ImpriMed 正在开发基于超过 350 万个数据点训练的 AI 模型，将真实世界数据与功能细胞分析相结合，以提高预测准确性。

ImpriMed is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch. The company has also established business partnerships with major U.S. hospitals as it builds its human health presence in North America.

ImpriMed 正准备将其针对血液癌症和血液感染的产品商业化，目标是在2027年第一季度获得美国食品药品监督管理局（FDA）许可和临床实验室改进修正案（CLIA）认证，以便在美国进行首次上市。该公司还与美国多家大型医院建立了业务合作伙伴关系，以构建其在北美的人类健康业务布局。

In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS) and is progressing through the approval and commercialization process. ImpriMed also collaborates with leading tertiary hospitals, including Catholic University Seoul St.

在韩国，ImpriMed 开发了用于多发性骨髓瘤预后和治疗反应预测的软件。该软件已被韩国食品药品安全部（MFDS）指定为创新医疗器械，并正在推进审批和商业化进程。ImpriMed 还与包括首尔圣母医院在内的多家领先三级医院开展合作。

Mary's Hospital, Seoul Asan Medical Center, and Gangneung Asan Hospital..

玛丽医院、首尔峨山医疗中心和江陵峨山医院。

ImpriMed's human healthcare expansion is supported by its commercial experience in veterinary precision oncology and its growing CRO business in drug development. In veterinary medicine, ImpriMed has performed more than 27,000 tests for canine and feline lymphoma to guide treatment decisions. A retrospective study showed a threefold increase in survival time and a fourfold improvement in treatment response, and the findings have been published in a peer-reviewed scientific journal.

ImpriMed向人类医疗健康领域的扩张，得益于其在兽医精准肿瘤学方面的商业化经验以及其在药物开发领域不断增长的合同研究组织（CRO）业务。在兽医医学领域，ImpriMed已开展超过27,000次犬猫淋巴瘤检测，以指导治疗决策。一项回顾性研究显示，患者生存时间增加了三倍，治疗反应率提高了四倍，相关研究成果已发表于同行评审的科学期刊。

ImpriMed's solutions are currently used by more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea..

ImpriMed 的解决方案目前已被美国、加拿大、英国、法国和韩国的 600 多家兽医医院采用。

ImpriMed was co-founded in Silicon Valley by CEO Sungwon Lim and CTO Jamin Koo, who studied together at KAIST and Stanford University. The company brings together expertise in biomedical research, AI modeling, clinical collaboration, and commercialization. Beyond North America, ImpriMed plans to expand into the European and Asian markets..

ImpriMed 由首席执行官 Sungwon Lim 和首席技术官 Jamin Koo 在硅谷联合创立，两人曾一同在韩国科学技术院（KAIST）和斯坦福大学求学。该公司汇聚了生物医学研究、人工智能建模、临床合作以及商业化方面的专业知识。除北美市场外，ImpriMed 还计划拓展欧洲和亚洲市场。

The $10 million bridge round follows ImpriMed's $23 million Series A in 2023. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, as well as follow-on investments from existing investors BonAngels and Han River Partners.

在ImpriMed于2023年完成2,300万美元的A轮融资之后，此次1,000万美元的过桥融资紧随其后。本轮融资由LB Investment领投，新投资者NAVER D2SF、Samsung Securities和Alois Ventures参与投资，现有投资者BonAngels和Han River Partners也进行了跟投。

NAVER D2SF continues to invest in healthcare startups targeting the North American market. Through NAVER D2SF's founder network, portfolio companies such as Soundable Health, PranaQ, and NubiLab share local market knowledge and operating experience, fostering collaboration across R&D and go-to-market strategy..

NAVER D2SF 持续投资面向北美市场的医疗保健初创企业。通过 NAVER D2SF 的创始人网络，Soundable Health、PranaQ 和 NubiLab 等投资组合公司共享本地市场知识和运营经验，促进在研发及市场进入策略方面的协作。

About NAVER D2SF

关于 NAVER D2SF

NAVER D2SF

NAVER D2SF

is NAVER's in-house corporate venture arm, supporting startups through investment and collaboration. Founded in 1999, NAVER has been Korea's leading search engine for more than 20 years and operates across commerce, content,

是NAVER旗下的企业内部风险投资部门，通过投资与协作支持初创企业。自1999年成立以来，NAVER已成为韩国领先的搜索引擎，拥有二十余年的行业领先地位，业务涵盖电子商务、内容等领域。

fintech

金融科技

, and cloud services. Guided by its technology vision of D2 (For Developers, By Developers), NAVER continues to develop new technologies and build global partnerships.

以及云服务。在“D2（For Developers, By Developers）”技术愿景的指引下，NAVER 持续开发新技术并建立全球合作伙伴关系。

To learn more, visit

了解更多，请访问

https://d2sf.naver.com

https://d2sf.naver.com

.

。

SOURCE NAVER D2SF

来源 NAVER D2SF

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示